Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 22Leukemia 13Leukemia, Myeloid, Chronic-Phase 11Gastrointestinal Stromal Tumors 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Myeloproliferative Disorders 4Neoplasms 3Neoplasm Metastasis 3Melanoma 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Myeloid 3Blast Crisis 3Thyroid Neoplasms 2Prostatic Neoplasms 2Primary Myelofibrosis 2Pancreatic Neoplasms 2Myelodysplastic Syndromes 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Brain Neoplasms 2Bone Marrow Diseases 2Uterine Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Thrombocytosis 1Thrombocythemia, Essential 1

Interventions

Dexamethasone 29Cyclophosphamide 21Rituximab 17Cytarabine 16Bortezomib 13Gemcitabine 12fludarabine 11Methotrexate 11Lenalidomide 10Filgrastim 10Vincristine 9Etoposide 9pomalidomide 8pembrolizumab 8Paclitaxel 8Azacitidine 8venetoclax 7carfilzomib 7Doxorubicin 7Docetaxel 7Cyclosporine 7Calcium Dobesilate 7Antilymphocyte Serum 7fludarabine phosphate 6Topotecan 6Temozolomide 6Radiotherapy 6Peripheral Blood Stem Cell Transplantation 6Mitoxantrone 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Recurrence × Imatinib Mesylate × Clear all
NCT00840450 2012-11-19

Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin

NYU Langone Health

Phase 2 Terminated
14 enrolled 10 charts
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡